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Introduction
Complete molecular remission (CMR) of chronic myeloid leukemia (CML), defined as the absence of detectable BCR-ABL1 mRNA in real-time reverse transcriptase quantitative PCR (RQ-PCR), is not equivalent to eradication of leukemia since there may be minimal residual disease (MRD) below the lower limit of detection of the test.
1,2 The withdrawal of imatinib treatment in carefully selected patients with chronic phase CML in a stable CMR for at least 2 years is followed by molecular relapse in around 60% of patients, whilst the remainder have a durable drug-free remission with follow-up of up to 4 years. 2, 3 The more potent tyrosine kinase inhibitors (TKIs), dasatinib and nilotinib are now widely used and highly effective in first-line treatment of chronic phase CML, 4,5 and may result in more patients achieving a CMR. The stability of CMR induced by a second generation TKI after treatment withdrawal is not known. Here we report, for the first time, the outcome of cessation of dasatinib in patients in CMR. Two out of three patients who achieved a CMR on dasatinib treatment remain in CMR 18 and 27 months after stopping TKI therapy.
Design and Methods
Cases of second generation TKI cessation were identified by a survey of members of the Australasian Leukaemia & Lymphoma Group (ALLG) involved in CML clinical trials. There were 3 cases of dasatinib cessation, but no patients stopping nilotinib in CMR were reported.
RQ-PCR monitoring and assessment of T cell receptor γ (TCR) clonality were performed in local diagnostic laboratories. BCR-ABL1 mRNA levels were measured in three different laboratories, all of which used the BCR control gene, and reported results on the BCR-ABL1
International Scale (IS). The lower limit of detection was in all cases >4.0 log below the standardised baseline. Ethical approval for the study was obtained from the two institutions where the patients were treated. For two of the patients the genomic BCR-ABL1 fusion sequence was identified in DNA extracted from cells obtained at the time of diagnosis, and patient-specific primers were designed for MRD analysis. 6 Quantitative BCR-ABL1 DNA PCR was performed on peripheral blood samples collected after withdrawal of dasatinib whilst in CMR. The limit of detection of the DNA PCR assay was approximately 10 -6 .
Results and discussion

Patient#1
A Molecular relapse occurred after 4 months with the BCR-ABL1 mRNA level rising to 0.89%.
Dasatinib treatment was resumed, without significant toxicity to date, and the patient regained CMR after 3 months ( Figure 1C ).
Dasatinib is a dual Src/ABL1 inhibitor which inhibits ABL1 with a potency in vitro of approximately 300 times that of imatinib. 7 It is associated with the emergence, in a significant proportion of patients, of lymphocytosis with evidence of T cell clonality by PCR. 8 The emergence of these aberrant lymphoid or NK cell populations has been reported to be associated with an improvement in molecular response, and possibly also with immunemediated side effects, such as pleural effusion. 8 These features led us to speculate that patients in CMR on dasatinib who manifest these immunological responses might be more likely to remain in CMR when the kinase inhibitor was withdrawn. We found a clonal T cell population in one of the two patients in stable CMR. The one patient who had a dasatinibinduced lymphocytosis relapsed when treatment was stopped. The impact of dasatinibrelated immunological phenomena on the stability of CMR after dasatinib treatment remains to be determined in a larger number of patients.
All three dasatinib-treated patients had evidence of MRD whilst in CMR (defined by conventional RQ-PCR): in two cases this was demonstrated by patient-specific DNA PCR, whereas in the third patient the presence of MRD was proven by molecular relapse. Despite the higher potency of dasatinib the level of MRD measured by sensitive DNA PCR was similar to that seen in patients in the ALLG CML8 study in patients in CMR. 2 The presence of BCR-ABL1-positive cells in the blood of a patient in a stable drug-free CMR appears to indicate that eradication of the leukemic clone is not a pre-requisite for the achievement of an operational cure of CML.
These results in three dasatinib-treated patients show close parallels to what has previously been reported in patients undergoing a trial of imatinib cessation. As in the imatinib data, if relapse occurred it did so within several months of therapy withdrawal, and was responsive to re-institution of the TKI. 3 The number of patients in this series is too small for us to determine whether the risk of relapse after dasatinib cessation differs from that after imatinib cessation. The patients that we describe all started dasatinib after imatinib failure in accelerated phase and/or with kinase domain mutations, and therefore constitute a group of higher risk patients than those in the STIM 3 or ALLG CML8 2 studies of imatinib cessation in CMR. These preliminary results suggest that the nature of the molecular remission on dasatinib is not qualitatively different from imatinib-induced CMR, at least in these patients with advanced disease features, despite the observation of immunological responses that appear to be relatively specific to dasatinib treatment. A prospective clinical trial of dasatinib withdrawal will be required to estimate accurately the probability of drug-free CMR and to identify factors that influence the risk of molecular relapse. The cases described here establish that durable disease control is possible following dasatinib cessation in CMR, despite prior imatinib failure and adverse disease features, including BCR-ABL1 kinase domain mutations. 
